Fabry Disease

  • Roscoe O. Brady

Fabry disease is the second most prevalent metabolic storage disorder of humans. Patients with this condition were originally described in 1898 by the dermatologists William Anderson in England and Johannes Fabry in Germany because of the occurrence of pigmented angiokeratomas on their skin, a common but not universal finding in this condition. It is an X-linked genetic condition frequently termed recessive, but heterozygous females often become symptomatic. With time, the kidneys, heart, brain, peripheral nerves, gastrointestinal tract, eyes, ears, lungs, and even the skeleton may become involved. A surprising aspect of this disorder is the nonuniformity of presentation of the signs and symptoms in various patients, even in siblings. Many patients experience pain in their hands and feet because of the peripheral neuropathy associated with this condition. It is frequently the initial sign of the disease in young affected males and frequently occurs somewhat later in heterozygous females (Brady and Schiffmann, 2005). The diagnosis of Fabry disease is not infrequently made by ophthalmologists because of the presence of corneal whorls (verticillata) and lens opacities along with tortuosity of the blood vessels of the retina. Vision is not appreciably impaired by these manifestations.


Enzyme Replacement Therapy Fabry Disease Gauche Disease Enzymatic Defect Heterozygous Female 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Abe, A., Gregory, S., Lee, L., Brady, R.O., Kulkarni, A., and Shayman, J.A., 2000, Reduction of globotriaosylceramide in Fabry disease mice by substrate deprivation. J Clin Invest. 105: 1563.CrossRefPubMedGoogle Scholar
  2. Baehner, F., Kampmann, C., Whybra, C., et al., 2003, Enzyme replacement therapy in heterozygous females with Fabry disease: Results of a phase IIIB study. J. Inherit. Metab. Dis. 26: 617.CrossRefPubMedGoogle Scholar
  3. Beck, M., Ricci, R., Widmer, U., et al., 2004, Fabry disease: Overall effects of agalsidase alpha treatment. Eur. J. Clin. Invest. 34: 838.CrossRefPubMedGoogle Scholar
  4. Brady, R.O., 1966, The sphingolipidoses. N. Engl J. Med. 275: 312.PubMedGoogle Scholar
  5. Brady, R.O., and Schiffmann, R., 2005, Fabry’s disease, in: Peripheral Neuropathy, Fourth Edition, P.J. Dyck and P.K. Thomas, Eds., Elsevier, Philadelphia, pp. 1893-1904.Google Scholar
  6. Brady, R.O., Gal, A.E., Bradley, R.M., et al., 1967a, Enzymatic defect in Fabry’s disease. Ceramidetrihexosidase deficency. N. Engl. J. Med. 276: 1163.Google Scholar
  7. Brady, R.O., Gal, A.E., Bradley, R.M., Martensson E., 1967b, The metabolism of cerami-detrihexosides. I. Purification and properties of an enzyme which cleaves the terminal galactose molecule of galactosylgalactosylglucosylceramide. J. Biol. Chem., 242: 1021.Google Scholar
  8. Brady, R.O., Murray, G.J., Moore, D.F., and Schiffmann, R., 2001, Enzyme replacement therapy in Fabry disease: J Inher Metab Dis. 24: S2 18.Google Scholar
  9. Brady, R.O., Murray, G.J., Oliver, K.L., et al., 1997, Management of neutralizing antibody to Ceredase in a patient with type 3 Gaucher disease. Pediatr, 100: e11-e14.CrossRefGoogle Scholar
  10. Brady, R.O., Tallman, J.F., Johnson, W.G., et al., 1973, Replacement therapy for inherited enzyme deficiency: Use of purified ceramidetrihexosidase in Fabry’s disease. N. Engl. J. Med. 289: 9.PubMedCrossRefGoogle Scholar
  11. Branton, M.H., Schiffmann, R., Sabnis, S.G., et al., 2002, Natural history of Fabry disease: Influence of α-galactosidase activity and genetic mutations on clinical course. Medicine 81: 122.CrossRefPubMedGoogle Scholar
  12. Cox, T., Lachmann, R., Hollak, C., et al., 2000, Novel oral treatment of Gaucher’s disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis. Lancet 355: 1481.CrossRefPubMedGoogle Scholar
  13. Dehout, F., Roland, D., Treille de Granseigne, S., et al., 2004, Relief of gastrointestinal symptoms under enzyme replacement therapy in patients with Fabry disease. J. Inherit. Metab. Dis. 27: 499.CrossRefPubMedGoogle Scholar
  14. Desnick, R.J., Ioannou, Y.A., and Eng, C.M., 2005, α−Galactosidase A deficiency: Fabry disease. In The Metabolic & Molecular Bases of Inherited Disease, ninth edition. C. R. Scriver, A.L. Beaudet, W.S. Sly, and D. Valle, Eds. McGraw-Hill, New York.Google Scholar
  15. Diaz-Font, A., Cormand, B., Chabas, A., Vilageliu, L., and Grinberg, D., 2003, Unsuccess-ful chimeraplast strategy for the correction of a mutation causing Gaucher disease. Blood Cell Mol Dis. 31: 183.CrossRefGoogle Scholar
  16. Donsante, A., Vogler, C., Muzyczka, N., et al., 2001, Observed incidence of tumori-genesis in long-term rodent studies of rAAV vectors. Gene Ther. 8: 1343.CrossRefPubMedGoogle Scholar
  17. Eng, C.M., Banikazemi, M., Gordon, R.E., et al., 2001a, A phase 1/2 clinical trial of enzyme replacement in Fabry disease: Pharmacokinetic, substrate clearance, and safety studies. Am. J. Hum. Genet. 68: 711.CrossRefGoogle Scholar
  18. Eng, C.M., Guffon, N., Wilcox, W.R., et al., 2001b, Safety and efficacy of recombinant human α-galactosidase A replacement therapy in Fabry’s disease. N Engl J Med. 345: 9.CrossRefGoogle Scholar
  19. Fan, J-Q, Ishgii, S., Asano, N., and Suzuki, Y., 1999, Accelerated transport and maturation of lysosomal α-galactosidase A in Fabry lymphoblasts by an enzyme inibitor, Nature Med. 5: 112.CrossRefPubMedGoogle Scholar
  20. Gamper, Jr., H.B., Cole-Trasuss, A., Metz, R., et al., 2000, A plausible mechanism for gene correction by chimeric oligonucleotides. Biochemistry 39: 5808.CrossRefPubMedGoogle Scholar
  21. Garman, S.C., and Garboczi, D.N., 2004, The molecular defect leading to Fabry disease: Structure of human α-galactosidase. J Mol Biol. 337: 319.CrossRefPubMedGoogle Scholar
  22. Hilz, M.J., Brys, M., Marthol, H., Stemper, B., and Dutsch, M., 2004, Enzyme replace-ment  therapy improves function of C-, Adelta-, and Abeta-nerve fibers in Fabry neuropathy. Neurology, 62: 1066.PubMedGoogle Scholar
  23. Hoffmann, B., de Lorenzo, A.G., Mehta, A, Beck, M., Widmer, U., and Ricci, R., 2005, Effects of enzyme replacement therapy on pain and health related quality of life in patients with Fabry disease: Data from FOS (Fabry Outcome Survey). J Med Genet. 42: 247.CrossRefPubMedGoogle Scholar
  24. Hoffmann, B., Reinhardt, D., and Koeetzko, B., 2004, Effect of enzyme-replacement therapy on gastrointestinal symptoms in Fabry disease. Eur. J. Gastroenter. Hepatol. 16: 1067.CrossRefGoogle Scholar
  25. Ioannou, Y.A., Zeidner, K.M., Gordon, R.E., and Desnick, R.J., 2001, Fabry disease: Preclinical studies demonstrate the effectiveness of α-galactosidase A replacement in enzyme-deficient mice. Am. J. Hum. Genet., 68: 14.CrossRefPubMedGoogle Scholar
  26. Johnson, W.G., and Brady, R.O., 1972, Ceramidetrihexosidase from human placenta. Methods Enzymol. XXVIII: 849.CrossRefGoogle Scholar
  27. Jung, S-C., Han, I.P., Limaye, A., et al., 2001, Adeno-associated viral vector-mediated gene transfer results in long-term enzymatic and functional correction in multiple organs of Fabry mice. Proc Nat Acad Sci USA. 98: 2676.CrossRefPubMedGoogle Scholar
  28. Kay, M.A., 2003, Looking into the safety of AAV vectors. Nature 424: 251.CrossRefPubMedGoogle Scholar
  29. Kint, J.A., 1970, Fabry’s disease: α-Galactosidase deficiency, Science 167: 1268.CrossRefPubMedGoogle Scholar
  30. Kornreich, R., Desnick, R.J., and Bishop, D.F., 1989, Nucleotide sequence of the human alpha-galactosidase A gene. Nucleic Acids Res., 17: 3301.CrossRefPubMedGoogle Scholar
  31. Kusiak, J.W., Quirk, J.M., and Brady, R.O., 1978, Purification and properties of the two major isozymes of α-galactosidase from human placenta. J Biol Chem. 253: 184.PubMedGoogle Scholar
  32. Linthorst, G.E., Holalck, C.E.M., Donker-Koopoman, W.E., et al., 2004, Enzyme therapy for Fabry disease: Neutralizing antibodies toward agalsidase alpha and beta. Kidney Internat., 66: 1589.CrossRefGoogle Scholar
  33. Liu, L., Parekh-Olmedo, H., and Kmiec, E.B., 2003, The development and regulation of gene repair. Nature Rev Genet., 4: 679.CrossRefPubMedGoogle Scholar
  34. Lu, I-L., Lin, C-Y., Lin, S-B., et al., 2003, Correction/mutation of acid α-D-glucosidase gene by modified single-stranded oligonucleotides: In vitro and in vivo studies. Gene Ther. 10: 1910.CrossRefPubMedGoogle Scholar
  35. MacDermot, K.D., Holmes, A., and Miners, A.H., 2001a, Anderson-Fabry disease: Clinical manifestations and impact of disease in a cohort of 98 hemizygous males. J. Med. Genet. 38: 750.CrossRefGoogle Scholar
  36. MacDermot, K.D., Holmes, A., and Miners, A.H., 2001b, Anderson-Fabry disease: Clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. J. Med. Genet., 38: 769.CrossRefGoogle Scholar
  37. Mayes, J.S., Scheerer, J.B., Sifers, R.N., and Donaldson, M.L., 1981, Differential assay for lysosomal alpha-galactosidases in human tissues and its application to Fabry’s disease. Clin Chim Acta. 112: 247.CrossRefPubMedGoogle Scholar
  38. Miller, D.G., Petek, L.M., and Russell, D.W., 2004, Adeno-associated virus vectors integrate at chromosome breakage sites. Nat. Genet. 36: 767l.CrossRefGoogle Scholar
  39. Moore, D.F., Altarescu, G., Ling, G.S., et al., 2002, Elevated cerebral blood flow velocities in Fabry disease with reversal after enzyme replacement therapy. Stroke, 33: 525.CrossRefPubMedGoogle Scholar
  40. Moore, D.F., Hescovitch, P., and Schiffmann, R. 2001, Selective arterial distribution of cerebral hyperperfusion in Fabry disease. J. Neuroimaging 11: 303.CrossRefPubMedGoogle Scholar
  41. Moore, D.F., Scott, L.T., Galdwin, M.T., et al., 2001, Regional cerebrl hyperperfusion and nitric oxide pathway dysregulation in Fabry disease: Reversal by enzyme replacement therapy. Circulation 104: 1506.CrossRefPubMedGoogle Scholar
  42. Moore, D.F., Ye, F.Q., Brennan, M., et al., 2004, Ascorbate decreases Fabry cerebral hyperperfusion suggesting a reactive oxygen species abnormality: An arterial spin labeling study. JMRI, 20: 674.CrossRefPubMedGoogle Scholar
  43. Nakia, H., Wu, X., Fuess, S., et al., 2005, Large-scale molecular characterization of adeno associated virus vector integration in mouse liver. J Virol. 79: 3605.Google Scholar
  44. Ohshima, T., Murray, G.J., Swain, W.D., et al., 1997, α-Galactosidase A deficient mice: a model of Fabry disease. Proc. Natl. Acad. Sci. USA 94: 2540.CrossRefPubMedGoogle Scholar
  45. Ohshima, T., Schiffmann, R., Murray, G.J., et al., 1999, Aging accentuates and bone marrow transplantation ameliorates metabolic defects in Fabry disease mice. Proc. Natl. Acad. Sci. USA 96: 6423.CrossRefPubMedGoogle Scholar
  46. Park, J., Murray, G.J., Limaye, A., et al., 2003, Long-term correction of globotriao-sylceramide storage in Fabry mice by recombinant adeno-associated virus-mediated gene transfer. Proc Nat Acad Sci. USA 100: 3450.CrossRefPubMedGoogle Scholar
  47. Qin, G., Takenaka, T., Telsch, K., et al., 2001, Preselective gene therapy for Fabry disease. Proc Natl Acad. Sci. USA 98: 3428.CrossRefPubMedGoogle Scholar
  48. Ries, M., Gupta, S., Moore D.F., et al., 2005, Pediatric Fabry disease, Pediatr. 115: e344.CrossRefGoogle Scholar
  49. Schäfer, E., Baron, K., Widmer, U., et al., 2005, Thirty-four novel mutations of the GLA gene in 121 patients with Fabry disease. Hum. Mutation, Mutation in Brief #798 (2005) Online.Google Scholar
  50. Schiffmann, R., Floeter, M.K, Dambrosia, J.M., et al., 2003, Enzyme replacement therapy improves peripheral nerve and sweat function in Fabry disease. Muscle and Nerve 28: 703.CrossRefPubMedGoogle Scholar
  51. Schiffmann, R., Kopp, J.B., Austin, H.A., et al., 2001, Enzyme replacement therapy in Fabry disease. A randomized controlled trial. JAMA, 285: 2743.CrossRefPubMedGoogle Scholar
  52. Schiffmann, R., Murray, G.J., Treco, D., et al., 2000, Infusion of α-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease. Proc. Natl. Acad. Sci. USA 97: 365.CrossRefPubMedGoogle Scholar
  53. Schiffmann, R., Ries, M., Flaherty, J.T., and Brady, R.O., 2006, Long-term therapy with agalsidase alpha for Fabry disease: Safety and effects on renal function. In preparation. Shabbeer, J, Robinsin, M., and Desnick, R.J., 2005, Detection of α-galactosidase A mutations causing Fabry disease by denaturing high performance liquid chromatography. Hum. Mutat., 25: 299.Google Scholar
  54. Sweeley, C.C., and Klionsky, B., 1963, Fabry’s disease: Classification as a sphingo-lipidoses and partial characterization of a novel glycolipid. J. Biol. Chem. 238: 3148.PubMedGoogle Scholar
  55. Takenaka, T., Hendrickson, D.S., Tworek, D.M., et al., 1999a, Enzymatic and functional correction along with long-term enzyme secretion from transduced bone marrow hematopoietic stem/progenitor and stromal cells derived from patients with Fabry disease. Exp Hematol. 27: 1149.CrossRefGoogle Scholar
  56. Takenaka, T., Murray G.J., Quin, G., et al., 2000, Long-term enzyme correction and lipid reduction in multiple organs of primary and secondary transplanted Fabry mice receiving transduced bone marrow cells. Proc. Natl. Acad. Sci. USA 97: 7515.CrossRefPubMedGoogle Scholar
  57. Takenaka, T., Quin, G., Brady, R.O., and Medin, J.A., 1999b, Circulating alpha-galacto-sidase A derived from transduced bone marrow cells: relevance for corrective gene transfer for Fabry disease, Hum Gene Ther. 10: 1931.CrossRefGoogle Scholar
  58. Weidemann, F., Breunig, F., Deer, M., et al., 2003, Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: A prospective strain rate imaging study. Circulation 108: 1299.CrossRefPubMedGoogle Scholar
  59. Wilcox, W.R., Banikazemi, M., Gufon, N., et al., 2004, Long term safety and efficacy, of enzyme replacement theray for Farby disease. Am. J. Hum. Genet. 75: 65.CrossRefPubMedGoogle Scholar
  60. Ziegler, R.J., Lonning, S.M., Armentano, D., et al., 2004, AAV2 vector harboring a liver- restricted promoter facilitates sustained exression of the therapeutic levels of α-galactosidase A and the induction of immune tolerance in Fabry mice. Mol. Ther. 9: 231.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  • Roscoe O. Brady
    • 1
  1. 1.National Institute of Neurological Disorders and strokeNational Institutes of HealthBethesdaUSA

Personalised recommendations